Immunomodulator

It is September once again, time for us to review the state of the anti-inflammatory landscape in the world of dry eye disease.

Half of patients with long COVID demonstrate persistent inflammation and may potentially benefit from immunomodulation, according to data.

Cumulative exposure to immunomodulators increased the risk for high-grade cervical intraepithelial neoplasia and cervical cancer in women with inflammatory bowel disease, according to data from Alimentary Pharmacology & Therapeutics.

WASHINGTON — Pegylated interferon alpha potentiated the antiviral activity of VIR-2218 in a small subset of noncirrhotic patients with chronic hepatitis B, according to preliminary data presented at The Liver Meeting.

Man, this sure is not turning into one of those “nothing to see here” columns.

Mesalamine correlated with the longest life expectancy among older adult patients with inflammatory bowel disease, according to research published in BMC Gastroenterology.

As many as 27.9% of immunomodulatory or immunosuppressive regimens were changed around the time of COVID-19 vaccination, with patients responsible for most modifications, according to data published in The Lancet Rheumatology.

WAILEA, Hawaii — Lifitegrast and cyclosporine are not only useful for long-term management of dry eye disease but are also effective in pre-cataract surgery patients with dry eye, according to a speaker at Hawaiian Eye 2021.

Response-adapted intensification treatment with a bortezomib-based regimen improved PFS among patients with newly diagnosed multiple myeloma who achieved minimal or partial response to immunomodulatory induction therapy, according to results of a randomized phase 3 study published in The Lancet Haematology.